-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HB-202 in Squamous Cell Carcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. HB-202 in Squamous Cell Carcinoma Drug Details: HB-202 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IMSA-101 in Gastroesophageal (GE) Junction Carcinomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IMSA-101 in Gastroesophageal (GE) Junction Carcinomas report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IMSA-101 in Gastroesophageal (GE) Junction Carcinomas Drug Details: IMSA-101...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AVA-6000 in Esophageal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AVA-6000 in Esophageal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AVA-6000 in Esophageal Cancer Drug Details: AVA-6000 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mirdametinib in Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mirdametinib in Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mirdametinib in Ovarian Cancer Drug Details: mirdametinib (PD-0325901) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Subasumstat in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Subasumstat in Follicular Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Subasumstat in Follicular Lymphoma Drug Details: TAK-981 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HB-201 in Head And Neck Squamous Cell Carcinoma (HNSC)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. HB-201 in Head And Neck Squamous Cell Carcinoma (HNSC) Drug Details: HB-201 (TheraT) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nogapendekin Alfa in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nogapendekin Alfa in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nogapendekin Alfa in Triple-Negative Breast Cancer (TNBC) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Enzalutamide in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Enzalutamide in Refractory Multiple Myeloma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Enzalutamide in Refractory Multiple Myeloma Drug Details: Enzalutamide (Xtandi) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HB-0045 in Sarcomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HB-0045 in Sarcomas report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HB-0045 in Sarcomas Drug Details: HB-0045 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HB-0036 in Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HB-0036 in Melanoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.HB-0036 in Melanoma Drug Details:HB-0036 a bi-specific antibody is under development for the treatment...